Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK.
J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1112-8. doi: 10.1136/jnnp.2011.240366. Epub 2011 May 18.
Our understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.
A representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn-Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr‘aphic, clinical and genetic variables was evaluated using survival analysis.
Axial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn-Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.
Dementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.
我们对特发性帕金森病(PD)的自然史的了解仍然有限。在潜在的疾病修饰疗法时代,迫切需要研究评估从发病开始的治疗后 PD 的自然演变,以便为临床试验确定相关的结局指标。以前没有研究从诊断点开始对未经选择的患者进行随访,以了解疾病的进展情况。
对 132 例 PD 患者的代表性队列进行了随访,最长时间为 7.9 年(平均 5.2 年)。每 18 个月进行一次全面的临床和神经心理学评估。使用经过充分验证的临床测量方法(统一帕金森病评定量表和 Hoehn-Yahr 量表上的运动进展和运动障碍的发展,根据 DSM-IV 标准确定痴呆的发病)评估疾病进展。使用多层次线性模型绘制帕金森病症状和体征随时间的自然和进展速度。使用生存分析评估基线人口统计学、临床和遗传变量的预后重要性。
轴性(步态和姿势)症状比 PD 的其他运动特征进展更快,似乎是疾病进展的最佳指标。相反,传统的结局指标随着时间的推移变化相对不敏感。姿势不稳(Hoehn-Yahr 第 3 期)的发病越早,与发病时年龄越大有关,对生活质量有重大影响。
痴呆风险与年龄增加、基线语义流畅性受损和 MAPT H1/H1 基因型有关。疾病修饰疗法的疗效可能更有意义地评估其在延迟 PD 的主要里程碑(如姿势不稳和痴呆)方面的效果,因为这些对患者的影响最大。